What Stembio Cell Technologies does

Stembio Cell Technologies (Stembio Cell and Tissue Technologies Inc.) is a privately held biotechnology company founded in 2020 and headquartered within the TÜBİTAK Marmara Teknokent (MARTEK) R&D and Innovation zone in Gebze, Kocaeli, Turkey. The company operates as Turkey's first and only hybrid cell and tissue processing center, producing human-derived cellular and tissue products under cGMP and cGTP standards with FDA facility registration, EATCB accreditation, and ISO 9001/14001/45001 certifications. Its infrastructure combines cGMP B and A class sterile production areas within cGMP B/C laboratories, full in-house quality control (sterility, pyrogenicity, flow-cytometry, tumorigenicity), and cryopreservation capacity for 20,000 cellular products, 10,000 cord blood units, and 10,000 tissue products held in liquid nitrogen and -86°C systems.

Stembio monetizes through eight sub-brands organized across three primary revenue mechanics: recurring cord blood and tissue banking subscriptions (STEMCORD), recurring cellular therapy product manufacturing and banking (STEMBIOCELL), one-time human allograft tissue product sales (STEMTISSUE), and regenerative/aesthetic hardware and professional services (EXOSTEM, STEMEST, STEMREGEN, STEMGENE, STEMANIMA). Distribution is hybrid: physician-directed and direct-to-hospital for clinical products (cardiovascular, orthopedic, ophthalmic grafts; cellular therapies), and direct-to-consumer for cord blood banking through website and phone channels. Strategic customers and partners include Yakın Doğu Üniversitesi Hastanesi and Dr. Suat Günsel Girne Üniversitesi Hastanesi in TRNC, LimbuStem for limbal stem cell therapies, and US-based Global Stem Cells Group (partnership signed at ISSCA 2023).

The company is led by Chairman İbrahim Özsu, CEO İlker Halbutoğfulları, and General Medical Director Prof. Dr. Utku Ateş (Histology and Embryology), with Doç. Dr. Durmuş Burgucu as Medical Director. It operates a single-headquarter model serving Turkey and (via partnership) TRNC, with no disclosed funding rounds, parent company, or revenue figures. Quantified value capture to date is framed around Turkey's previously $600M annual tissue/cell import cost, which the company positions itself as reducing via domestic cGMP production.

Name

Stembio Cell Technologies

Legal name

Stembio Cell and Tissue Technologies Inc.

Website

https://stembio.com.tr

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

Stembio Cell Technologies is Turkey's first and only hybrid cGMP-certified cell and tissue processing center, founded in 2020 in Gebze, producing and banking cord blood, cellular therapies, tissue allografts, exosomes, gene therapies, and veterinary stem cell products for hospitals, physicians, and families.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell Therapies (Autologous & Allogeneic) (HLAMANAA)

Keywords

• Stem cell therapy
• Cord blood banking
• Regenerative medicine
• Tissue allografts
• Cellular therapy

Headquarters

HQ city

Gebze

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Cord Blood and Cord Tissue Banking: Storage services for cord blood and cord tissue containing hematopoietic stem cells for family use (autologous) or donation (allogeneic). Services include collection kits, processing, and long-term cryopreservation storage.
2. Cellular Therapy Products: Production and banking of cellular therapy products including mesenchymal stem cells (MKH), hematopoietic stem cells (HKH), immunotherapy products, and tissue engineering cellular products under cGMP standards.
3. Human Tissue Allograft Products: Processing, storage and distribution of human allograft tissue products including cardiovascular tissues (heart valves, conduits, pericardial patches, vascular patches), musculoskeletal tissues, cornea, amniotic membrane, and skin products.
4. Regenerative Medicine Products: StemRegen products including stromal vascular fraction (Adinizer) and platelet-rich plasma (PRP) for regenerative applications.
5. Veterinary Cellular Therapy: StemAnima provides stem cell therapies for animals including treatments for paralysis, kidney failure, autoimmune diseases, and allergies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Stembio Cell Technologies is a biotechnology center that manufactures and supplies stem cell-based cellular therapy products, human tissue allografts, mesenchymal stem cell-derived exosome products, and regenerative medicine kits, while simultaneously operating a cord blood and cord tissue banking service. Operating under cGMP/cGTP standards at the TÜBİTAK MARTEK R&D zone in Gebze, Turkey, the company serves both individual families (subscription cord blood banking) and healthcare institutions (cellular therapy and tissue products for clinical use), and has expanded into veterinary stem cell therapies.

Product overview

Stembio Cell Technologies operates as a biotechnology base offering a portfolio of specialized sub-brands focused on stem cell, tissue, and gene technology products and services. The company provides eight distinct product lines: EXOSTEM (mesenchymal stem cell-derived exosomes for skin rejuvenation), STEMBIOCELL (cellular therapy products manufacturing and banking), STEMCORD (cord blood and tissue banking), STEMEST (aesthetic applications and facial rejuvenation), STEMTISSUE (human-derived tissue grafts banking), STEMGENE (gene therapies), STEMREGEN (regenerative medicine applications), and STEMANIMA (veterinary stem cell therapies). The company functions as Turkey's first and only hybrid cell and tissue center, operating under cGMP/cGTP standards, and processes human-derived cells and tissues for clinical use.

Differentiator

Problem solved

Functional benefit

Brands

• EXOSTEM: Mesenchymal Stem Cell Derived Exosome product for skin rejuvenation and cell renewal
• STEMBIOCELL
• STEMCORD
• STEMEST
• STEMTISSUE
• STEMGENE
• STEMREGEN
• STEMANIMA

Products and services

• EXOSTEM Mesenchymal stem cell-derived exosome product line developed and supplied by Stembio Cell Technologies, intended for use in regenerative medicine applications and targeted at healthcare providers and clinical users.
• STEMBIOCELL STEMBIOCELL is Stembio's cellular therapy products line, manufacturing and supplying stem cell-based therapeutic products under cGMP/cGTP conditions for clinical use by hospitals, physicians, and healthcare providers.
• STEMCORD STEMCORD is Stembio's cord blood and cord tissue banking service, providing collection, processing, cryopreservation at –196 °C, and long-term storage for expectant and new parents (families) under cGMP/cGTP standards.
• STEMEST STEMEST is Stembio's aesthetic stem cell applications sub-brand, offering stem cell-based aesthetic products and services for clinical aesthetic providers in Turkey's cosmetic medicine market.
• STEMTISSUE STEMTISSUE is Stembio's human tissue allograft sub-brand, manufacturing and supplying tissue products processed under cGMP/cGTP conditions for surgical and clinical use by hospitals and physicians.
• STEMGENE STEMGENE is Stembio's gene therapy research and development sub-brand, conducting gene therapy research activities as part of the company's biotechnology portfolio.
• STEMREGEN STEMREGEN is Stembio's regenerative medicine applications sub-brand, supplying regenerative medicine kits such as Adinizer and PRP-based products for clinical use by hospitals, clinics, and aesthetic providers.
• STEMANIMA STEMANIMA is Stembio's veterinary stem cell therapy sub-brand, providing stem cell-based regenerative therapies for companion animals (e.g., cats and dogs), including treatment of conditions such as feline gingivostomatitis, sold directly to veterinary clinics.

Quantifiable outcome

• Turkey's annual $600 million tissue and cell import costs have started to decrease due to StemBio's domestic production capabilities
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Global Stem Cells GroupflagshipStrategic or Co-development Partner · 1 January 2023Strategic partnership announced at ISSCA World Regenerative Medicine Congress 2023 in Istanbul. Global Stem Cells Group (USA-based, world leader in regenerative medicine) and StemBio signed a collaboration protocol to advance R&D activities in regenerative medicine. Key attendees included Benito Novas (Founder of Global Stem Cells Group), İbrahim Özsu (StemBio Chairman), İlker Halbutoğulları (CEO), and David Christensen (President of Global Stem Cells Group).
• Yakın Doğu Üniversitesi HastanesicoreStrategic or Co-development PartnerJoint establishment of 'Hücre Doku ve Rejeneratif Uygulamalar ve Araştırma Merkezi' (Cell Tissue and Regenerative Applications and Research Center) - the first and only center of its kind in TRNC. The center provides stem cell therapies in orthopedics, plastic reconstructive surgery, urology, gynecology, and physical medicine.
• Dr. Suat Günsel Girne Üniversitesi HastanesicoreStrategic or Co-development PartnerPartnership in establishing the Cell Tissue and Regenerative Applications and Research Center in TRNC. Contributed to the first stem cell therapies being administered in Northern Cyprus.
• LimbuStemcoreStrategic or Co-development PartnerCollaboration for limbal stem cell production and transplantation. StemBio provides laboratory facilities meeting stem cell and organ transplantation regulations, while LimbuStem (founded by Prof. Dr. Özlem Barut Selver and Dr. Mehmet Gürdal) provides the technology for limbal stem cell culture and transplantation. The partnership enables treatment for patients with limbal stem cell deficiency in Turkey.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cryo-Cell International: US-listed cord blood and tissue banking company operating a similar family-banking subscription model to StemBio's STEMCORD line. Directly comparable on core banking service, regulatory positioning, and consumer go-to-market.
• ViaCord (Revvity): Cord blood and cord tissue banking service now part of Revvity (formerly PerkinElmer). Competes with StemBio's STEMCORD on family banking subscriptions, processing standards, and long-term cryopreservation storage.
• Cord Blood Registry (CBR) / California Cryobank: One of the largest family cord blood banking services globally, operating under the same subscription-recurring model as StemBio's STEMCORD. Direct overlap on consumer banking and processing technology.
• VetStem Biopharma: US veterinary stem cell therapy provider offering autologous stem cell treatments for companion animals and horses. Directly comparable to StemBio's STEMANIMA veterinary line on indication scope and practice-level distribution.
• Pluristem Therapeutics: Clinical-stage developer of placenta-derived cellular therapy products. Comparable to StemBio's STEMBIOCELL mesenchymal stem cell product line in underlying technology (allogeneic MSC therapies) and target indications.

Broad incumbents

• LifeNet Health: Large non-profit tissue banking and allograft manufacturer with global distribution. Comparable to StemBio's STEMTISSUE allograft portfolio across cardiovascular, musculoskeletal, and skin grafts, though with much broader scale and geography.
• Mesoblast: Commercial-stage cellular medicine company developing MSC-based therapies for inflammatory and immunologic conditions. Overlaps with StemBio's mesenchymal stem cell manufacturing capabilities and clinical applications.
• RTI Surgical: Commercial-stage surgical implant company with a substantial allograft tissue portfolio. Comparable to StemBio's STEMTISSUE cardiovascular and musculoskeletal tissue graft business in product type, regulatory pathway, and hospital-channel distribution.

Regional players

• Cryo-Save (Esperite): European family stem cell banking group with operations across multiple EMEA countries. Comparable to StemBio's STEMCORD service and represents the closest regional peer for stem cell banking business model.

Others

• Global Stem Cells Group: US-based regenerative medicine company focused on training, products, and clinical services. Listed because it is StemBio's named strategic partner and operates in the same regenerative medicine ecosystem, though the business model (training/advisory) differs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/StembioCtech
• Facebookfacebook.com/stembiocelltech
• LinkedInlinkedin.com/company/stembio-cell-technologies
• Instagraminstagram.com/STEMBIOcelltech

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stembio Cell Technologies